ID,Description,GeneRatio,BgRatio,pvalue,p.adjust,qvalue,geneID,Count
R-HSA-211945,Phase I - Functionalization of compounds,6/108,106/11091,0.000574988826492003,0.27874818812402,0.257153857760776,13/23491/9420/4129/5443/5447,6
R-HSA-211859,Biological oxidations,8/108,222/11091,0.00143724181771725,0.27874818812402,0.257153857760776,13/23491/55748/9420/4129/5443/5447/6820,8
R-HSA-210500,Glutamate Neurotransmitter Release Cycle,3/108,24/11091,0.00156600105687652,0.27874818812402,0.257153857760776,22999/6507/6616,3
R-HSA-201451,Signaling by BMP,3/108,31/11091,0.00331024184501341,0.330313067486098,0.304724059892557,658/64388/9241,3
R-HSA-168799,Neurotoxicity of clostridium toxins,2/108,10/11091,0.00401756993296111,0.330313067486098,0.304724059892557,6616/9900,2
R-HSA-8963691,Phenylalanine and tyrosine metabolism,2/108,11/11091,0.00487925599531014,0.330313067486098,0.304724059892557,80150/2184,2
R-HSA-196071,Metabolism of steroid hormones,3/108,36/11091,0.0050762818478459,0.330313067486098,0.304724059892557,3292/3294/5443,3
R-HSA-176974,Unwinding of DNA,2/108,12/11091,0.00581804274016935,0.330313067486098,0.304724059892557,51659/4173,2
R-HSA-8853659,RET signaling,3/108,40/11091,0.00682971726746544,0.330313067486098,0.304724059892557,2886/4902/5295,3
R-HSA-71240,Tryptophan catabolism,2/108,14/11091,0.00792072092053737,0.330313067486098,0.304724059892557,23498/120103,2
R-HSA-198933,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,5/108,133/11091,0.00958027883079389,0.330313067486098,0.304724059892557,933/3821/196500/6441/79865,5
R-HSA-5693567,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),5/108,134/11091,0.00987628059842649,0.330313067486098,0.304724059892557,675/9156/8347/8339/7468,5
R-HSA-264642,Acetylcholine Neurotransmitter Release Cycle,2/108,17/11091,0.0116148441167852,0.330313067486098,0.304724059892557,22999/6616,2
R-HSA-5693538,Homology Directed Repair,5/108,140/11091,0.0117854354155501,0.330313067486098,0.304724059892557,675/9156/8347/8339/7468,5
R-HSA-181429,Serotonin Neurotransmitter Release Cycle,2/108,18/11091,0.0129843578895934,0.330313067486098,0.304724059892557,22999/6616,2
R-HSA-181430,Norepinephrine Neurotransmitter Release Cycle,2/108,18/11091,0.0129843578895934,0.330313067486098,0.304724059892557,22999/6616,2
R-HSA-210993,Tie2 Signaling,2/108,18/11091,0.0129843578895934,0.330313067486098,0.304724059892557,2886/5295,2
R-HSA-5676594,TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway,2/108,18/11091,0.0129843578895934,0.330313067486098,0.304724059892557,9020/115650,2
R-HSA-69473,G2/M DNA damage checkpoint,4/108,94/11091,0.0132697817187631,0.330313067486098,0.304724059892557,9156/8347/8339/7468,4
R-HSA-112310,Neurotransmitter release cycle,3/108,51/11091,0.0133287332284183,0.330313067486098,0.304724059892557,22999/6507/6616,3
R-HSA-416700,Other semaphorin interactions,2/108,19/11091,0.014420549982894,0.330313067486098,0.304724059892557,64218/80031,2
R-HSA-888590,"GABA synthesis, release, reuptake and degradation",2/108,19/11091,0.014420549982894,0.330313067486098,0.304724059892557,22999/6616,2
R-HSA-5693607,Processing of DNA double-strand break ends,4/108,97/11091,0.0147484116674265,0.330313067486098,0.304724059892557,9156/8347/8339/7468,4
R-HSA-1474165,Reproduction,5/108,154/11091,0.0171840326025234,0.330313067486098,0.304724059892557,675/8347/8339/3306/5460,5
R-HSA-8957322,Metabolism of steroids,5/108,155/11091,0.0176230370822948,0.330313067486098,0.304724059892557,8029/9420/3292/3294/5443,5
R-HSA-140875,Common Pathway of Fibrin Clot Formation,2/108,22/11091,0.0191152646265624,0.330313067486098,0.304724059892557,2157/5627,2
R-HSA-389357,CD28 dependent PI3K/Akt signaling,2/108,22/11091,0.0191152646265624,0.330313067486098,0.304724059892557,9020/5295,2
R-HSA-392154,Nitric oxide stimulates guanylate cyclase,2/108,22/11091,0.0191152646265624,0.330313067486098,0.304724059892557,4843/5153,2
R-HSA-8866654,E3 ubiquitin ligases ubiquitinate target proteins,3/108,59/11091,0.0196784884627931,0.330313067486098,0.304724059892557,8347/8339/5193,3
R-HSA-140837,Intrinsic Pathway of Fibrin Clot Formation,2/108,23/11091,0.0208043402314955,0.330313067486098,0.304724059892557,2157/5627,2
R-HSA-212676,Dopamine Neurotransmitter Release Cycle,2/108,23/11091,0.0208043402314955,0.330313067486098,0.304724059892557,22999/6616,2
R-HSA-2453902,The canonical retinoid cycle in rods (twilight vision),2/108,23/11091,0.0208043402314955,0.330313067486098,0.304724059892557,3292/8608,2
R-HSA-6785807,Interleukin-4 and Interleukin-13 signaling,4/108,108/11091,0.0210440437464132,0.330313067486098,0.304724059892557,3598/4843/5295/5443,4
R-HSA-9709603,Impaired BRCA2 binding to PALB2,2/108,24/11091,0.0225532801564609,0.330313067486098,0.304724059892557,675/9156,2
R-HSA-69481,G2/M Checkpoints,5/108,167/11091,0.023479940586661,0.330313067486098,0.304724059892557,9156/8347/8339/4173/7468,5
R-HSA-9701192,Defective homologous recombination repair (HRR) due to BRCA1 loss of function,2/108,25/11091,0.0243607812365269,0.330313067486098,0.304724059892557,675/9156,2
R-HSA-9701193,Defective homologous recombination repair (HRR) due to PALB2 loss of function,2/108,25/11091,0.0243607812365269,0.330313067486098,0.304724059892557,675/9156,2
R-HSA-9704331,Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function,2/108,25/11091,0.0243607812365269,0.330313067486098,0.304724059892557,675/9156,2
R-HSA-9704646,Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function,2/108,25/11091,0.0243607812365269,0.330313067486098,0.304724059892557,675/9156,2
R-HSA-5693532,DNA Double-Strand Break Repair,5/108,170/11091,0.0251190725897293,0.330313067486098,0.304724059892557,675/9156/8347/8339/7468,5
R-HSA-373755,Semaphorin interactions,3/108,65/11091,0.0253611156684083,0.330313067486098,0.304724059892557,3984/64218/80031,3
R-HSA-211897,Cytochrome P450 - arranged by substrate type,3/108,66/11091,0.0263851565485568,0.330836690002046,0.305207117920279,9420/5443/5447,3
R-HSA-1500620,Meiosis,4/108,117/11091,0.0272588590706588,0.330836690002046,0.305207117920279,675/8347/8339/3306,4
R-HSA-211976,Endogenous sterols,2/108,27/11091,0.0281463504042167,0.330836690002046,0.305207117920279,9420/5443,2
R-HSA-5693554,Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA),2/108,27/11091,0.0281463504042167,0.330836690002046,0.305207117920279,675/9156,2
R-HSA-5693571,Nonhomologous End-Joining (NHEJ),3/108,68/11091,0.0284990407117867,0.330836690002046,0.305207117920279,8347/8339/7468,3
R-HSA-388841,Costimulation by the CD28 family,3/108,69/11091,0.029588820284885,0.336179362385714,0.310135899066655,9020/5295/5526,3
R-HSA-186763,Downstream signal transduction,2/108,29/11091,0.0321510037938766,0.350380327059799,0.323236729871843,2886/5295,2
R-HSA-5683826,Surfactant metabolism,2/108,29/11091,0.0321510037938766,0.350380327059799,0.323236729871843,150/6441,2
R-HSA-9824439,Bacterial Infection Pathways,3/108,73/11091,0.0341658354338831,0.364891122433871,0.336623389116995,4843/6616/9900,3
R-HSA-5339562,Uptake and actions of bacterial toxins,2/108,31/11091,0.0363649944343377,0.371300456459545,0.342536198744465,6616/9900,2
R-HSA-114608,Platelet degranulation,4/108,129/11091,0.0370918309658031,0.371300456459545,0.342536198744465,1191/2157/3699/5627,4
R-HSA-69190,DNA strand elongation,2/108,32/11091,0.0385475246324297,0.371300456459545,0.342536198744465,51659/4173,2
R-HSA-983695,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,2/108,32/11091,0.0385475246324297,0.371300456459545,0.342536198744465,933/5295,2
R-HSA-5693565,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,3/108,77/11091,0.0390886551083746,0.371300456459545,0.342536198744465,8347/8339/7468,3
R-HSA-1221632,Meiotic synapsis,3/108,78/11091,0.0403728523941126,0.371300456459545,0.342536198744465,8347/8339/3306,3
R-HSA-5693606,DNA Double Strand Break Response,3/108,78/11091,0.0403728523941126,0.371300456459545,0.342536198744465,8347/8339/7468,3
R-HSA-389356,CD28 co-stimulation,2/108,33/11091,0.0407788647591705,0.371300456459545,0.342536198744465,9020/5295,2
R-HSA-8852135,Protein ubiquitination,3/108,79/11091,0.0416782783637092,0.371300456459545,0.342536198744465,8347/8339/5193,3
R-HSA-76005,Response to elevated platelet cytosolic Ca2+,4/108,134/11091,0.0417191524111849,0.371300456459545,0.342536198744465,1191/2157/3699/5627,4
R-HSA-76002,"Platelet activation, signaling and aggregation",6/108,263/11091,0.0433223457538809,0.37924807594381,0.3498681244662,150/1191/2157/3699/5295/5627,6
R-HSA-9709570,Impaired BRCA2 binding to RAD51,2/108,35/11091,0.0453834392193576,0.390883170050597,0.360601860011195,675/9156,2
R-HSA-390522,Striated Muscle Contraction,2/108,36/11091,0.0477544484765054,0.393980622280869,0.363459355859347,4634/7136,2
R-HSA-5693568,Resolution of D-loop Structures through Holliday Junction Intermediates,2/108,36/11091,0.0477544484765054,0.393980622280869,0.363459355859347,675/9156,2
R-HSA-1483255,PI Metabolism,3/108,84/11091,0.0485204642629148,0.393980622280869,0.363459355859347,9108/5295/57664,3
R-HSA-912446,Meiotic recombination,3/108,85/11091,0.0499511797038301,0.393980622280869,0.363459355859347,675/8347/8339,3
R-HSA-5693537,Resolution of D-Loop Structures,2/108,37/11091,0.050169817069474,0.393980622280869,0.363459355859347,675/9156,2
R-HSA-8964043,Plasma lipoprotein clearance,2/108,37/11091,0.050169817069474,0.393980622280869,0.363459355859347,23491/8029,2
R-HSA-418346,Platelet homeostasis,3/108,88/11091,0.054365823360256,0.420263958588664,0.387706549614616,4843/5153/5526,3
R-HSA-140877,Formation of Fibrin Clot (Clotting Cascade),2/108,39/11091,0.0551293653235194,0.420263958588664,0.387706549614616,2157/5627,2
R-HSA-9616222,Transcriptional regulation of granulopoiesis,3/108,89/11091,0.0558777922468073,0.420263958588664,0.387706549614616,1050/8347/8339,3
R-HSA-5693616,Presynaptic phase of homologous DNA pairing and strand exchange,2/108,40/11091,0.0576714520633117,0.427729936136229,0.394594145696343,675/9156,2
R-HSA-9675136,Diseases of DNA Double-Strand Break Repair,2/108,41/11091,0.0602537118766274,0.434803812731338,0.401120016475983,675/9156,2
R-HSA-9701190,Defective homologous recombination repair (HRR) due to BRCA2 loss of function,2/108,41/11091,0.0602537118766274,0.434803812731338,0.401120016475983,675/9156,2
R-HSA-9696273,RND1 GTPase cycle,2/108,42/11091,0.0628751379111838,0.437444381416277,0.40355602306883,2886/5295,2
R-HSA-9821993,Replacement of protamines by nucleosomes in the male pronucleus,2/108,42/11091,0.0628751379111838,0.437444381416277,0.40355602306883,8347/8339,2
R-HSA-3214815,HDACs deacetylate histones,3/108,94/11091,0.063734871598988,0.437444381416277,0.40355602306883,92815/8347/8339,3
R-HSA-69620,Cell Cycle Checkpoints,6/108,292/11091,0.065416880102155,0.437444381416277,0.40355602306883,9156/8347/8339/4173/7468/5526,6
R-HSA-1433557,Signaling by SCF-KIT,2/108,43/11091,0.0655347387889553,0.437444381416277,0.40355602306883,2886/5295,2
R-HSA-5693579,Homologous DNA Pairing and Strand Exchange,2/108,43/11091,0.0655347387889553,0.437444381416277,0.40355602306883,675/9156,2
R-HSA-71291,Metabolism of amino acids and derivatives,7/108,367/11091,0.0668533366565996,0.440736812032397,0.406593392531366,80150/875/1734/2184/23498/57515/120103,7
R-HSA-418555,G alpha (s) signalling events,4/108,158/11091,0.0682694616120691,0.444584054888353,0.410142593510248,2838/157/5153/5443,4
R-HSA-977606,Regulation of Complement cascade,2/108,47/11091,0.0765355935667908,0.444844312425286,0.410382689168212,1191/5627,2
R-HSA-6811558,"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",3/108,106/11091,0.0845234753148789,0.444844312425286,0.410382689168212,9173/5295/5526,3
R-HSA-1227986,Signaling by ERBB2,2/108,50/11091,0.0851407224973899,0.444844312425286,0.410382689168212,2886/5295,2
R-HSA-171306,Packaging Of Telomere Ends,2/108,51/11091,0.0880718241002051,0.444844312425286,0.410382689168212,8347/8339,2
R-HSA-9675135,Diseases of DNA repair,2/108,51/11091,0.0880718241002051,0.444844312425286,0.410382689168212,675/9156,2
R-HSA-9843745,Adipogenesis,3/108,109/11091,0.0901229093923209,0.444844312425286,0.410382689168212,1050/1734/1959,3
R-HSA-425393,Transport of inorganic cations/anions and amino acids/oligopeptides,3/108,110/11091,0.092023343093929,0.444844312425286,0.410382689168212,6507/120103/6550,3
R-HSA-977225,Amyloid fiber formation,3/108,110/11091,0.092023343093929,0.444844312425286,0.410382689168212,8347/8339/9627,3
R-HSA-1250342,PI3K events in ERBB4 signaling,1/108,10/11091,0.0932544228010881,0.444844312425286,0.410382689168212,5295,1
R-HSA-159740,Gamma-carboxylation of protein precursors,1/108,10/11091,0.0932544228010881,0.444844312425286,0.410382689168212,5627,1
R-HSA-159782,Removal of aminoterminal propeptides from gamma-carboxylated proteins,1/108,10/11091,0.0932544228010881,0.444844312425286,0.410382689168212,5627,1
R-HSA-194002,Glucocorticoid biosynthesis,1/108,10/11091,0.0932544228010881,0.444844312425286,0.410382689168212,5443,1
R-HSA-209968,Thyroxine biosynthesis,1/108,10/11091,0.0932544228010881,0.444844312425286,0.410382689168212,1734,1
R-HSA-9758881,Uptake of dietary cobalamins into enterocytes,1/108,10/11091,0.0932544228010881,0.444844312425286,0.410382689168212,8029,1
R-HSA-1660499,Synthesis of PIPs at the plasma membrane,2/108,53/11091,0.0940229290440352,0.444844312425286,0.410382689168212,5295/57664,2
R-HSA-199418,Negative regulation of the PI3K/AKT network,3/108,113/11091,0.0978240405819671,0.444844312425286,0.410382689168212,9173/5295/5526,3
R-HSA-110330,Recognition and association of DNA glycosylase with site containing an affected purine,2/108,55/11091,0.100086987611255,0.444844312425286,0.410382689168212,8347/8339,2
R-HSA-110331,Cleavage of the damaged purine,2/108,55/11091,0.100086987611255,0.444844312425286,0.410382689168212,8347/8339,2
R-HSA-73927,Depurination,2/108,55/11091,0.100086987611255,0.444844312425286,0.410382689168212,8347/8339,2
R-HSA-159854,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",1/108,11/11091,0.102091939481666,0.444844312425286,0.410382689168212,5627,1
R-HSA-1660517,Synthesis of PIPs at the late endosome membrane,1/108,11/11091,0.102091939481666,0.444844312425286,0.410382689168212,9108,1
R-HSA-193048,Androgen biosynthesis,1/108,11/11091,0.102091939481666,0.444844312425286,0.410382689168212,5443,1
R-HSA-5655291,Signaling by FGFR4 in disease,1/108,11/11091,0.102091939481666,0.444844312425286,0.410382689168212,5295,1
R-HSA-5661231,Metallothioneins bind metals,1/108,11/11091,0.102091939481666,0.444844312425286,0.410382689168212,4494,1
R-HSA-9823739,Formation of the anterior neural plate,1/108,11/11091,0.102091939481666,0.444844312425286,0.410382689168212,5460,1
R-HSA-9610379,HCMV Late Events,3/108,116/11091,0.103770061334394,0.444844312425286,0.410382689168212,92815/8347/8339,3
R-HSA-69306,DNA Replication,4/108,186/11091,0.10792371508974,0.444844312425286,0.410382689168212,51659/8347/8339/4173,4
R-HSA-166658,Complement cascade,2/108,58/11091,0.109380670672465,0.444844312425286,0.410382689168212,1191/5627,2
R-HSA-186797,Signaling by PDGF,2/108,58/11091,0.109380670672465,0.444844312425286,0.410382689168212,2886/5295,2
R-HSA-174403,Glutathione synthesis and recycling,1/108,12/11091,0.110844111912711,0.444844312425286,0.410382689168212,55748,1
R-HSA-196791,Vitamin D (calciferol) metabolism,1/108,12/11091,0.110844111912711,0.444844312425286,0.410382689168212,8029,1
R-HSA-430116,GP1b-IX-V activation signalling,1/108,12/11091,0.110844111912711,0.444844312425286,0.410382689168212,5295,1
R-HSA-5685939,HDR through MMEJ (alt-NHEJ),1/108,12/11091,0.110844111912711,0.444844312425286,0.410382689168212,675,1
R-HSA-9027276,Erythropoietin activates Phosphoinositide-3-kinase (PI3K),1/108,12/11091,0.110844111912711,0.444844312425286,0.410382689168212,5295,1
R-HSA-9673767,"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",1/108,12/11091,0.110844111912711,0.444844312425286,0.410382689168212,5295,1
R-HSA-9673770,Signaling by PDGFRA extracellular domain mutants,1/108,12/11091,0.110844111912711,0.444844312425286,0.410382689168212,5295,1
R-HSA-9827857,Specification of primordial germ cells,1/108,12/11091,0.110844111912711,0.444844312425286,0.410382689168212,5460,1
R-HSA-9842663,Signaling by LTK,1/108,12/11091,0.110844111912711,0.444844312425286,0.410382689168212,5295,1
R-HSA-5617472,Activation of anterior HOX genes in hindbrain development during early embryogenesis,3/108,121/11091,0.113989637423293,0.444844312425286,0.410382689168212,1959/8347/8339,3
R-HSA-5619507,Activation of HOX genes during differentiation,3/108,121/11091,0.113989637423293,0.444844312425286,0.410382689168212,1959/8347/8339,3
R-HSA-110328,Recognition and association of DNA glycosylase with site containing an affected pyrimidine,2/108,60/11091,0.115699063584253,0.444844312425286,0.410382689168212,8347/8339,2
R-HSA-110329,Cleavage of the damaged pyrimidine,2/108,60/11091,0.115699063584253,0.444844312425286,0.410382689168212,8347/8339,2
R-HSA-73928,Depyrimidination,2/108,60/11091,0.115699063584253,0.444844312425286,0.410382689168212,8347/8339,2
R-HSA-163841,"Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation",2/108,61/11091,0.118892769400765,0.444844312425286,0.410382689168212,2157/5627,2
R-HSA-1362409,Mitochondrial iron-sulfur cluster biogenesis,1/108,13/11091,0.119511756638176,0.444844312425286,0.410382689168212,51312,1
R-HSA-2892247,"POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation",1/108,13/11091,0.119511756638176,0.444844312425286,0.410382689168212,5460,1
R-HSA-9637687,Suppression of phagosomal maturation,1/108,13/11091,0.119511756638176,0.444844312425286,0.410382689168212,4843,1
R-HSA-9006936,Signaling by TGFB family members,3/108,124/11091,0.120298937052399,0.444844312425286,0.410382689168212,658/64388/9241,3
R-HSA-73728,RNA Polymerase I Promoter Opening,2/108,62/11091,0.122108500109006,0.444844312425286,0.410382689168212,8347/8339,2
R-HSA-73929,"Base-Excision Repair, AP Site Formation",2/108,62/11091,0.122108500109006,0.444844312425286,0.410382689168212,8347/8339,2
R-HSA-9033241,Peroxisomal protein import,2/108,63/11091,0.125345534580896,0.444844312425286,0.410382689168212,4843/5193,2
R-HSA-1855183,"Synthesis of IP2, IP, and Ins in the cytosol",1/108,14/11091,0.12809568246261,0.444844312425286,0.410382689168212,9108,1
R-HSA-209952,Peptide hormone biosynthesis,1/108,14/11091,0.12809568246261,0.444844312425286,0.410382689168212,5443,1
R-HSA-3296469,Defects in cobalamin (B12) metabolism,1/108,14/11091,0.12809568246261,0.444844312425286,0.410382689168212,8029,1
R-HSA-3371568,Attenuation phase,1/108,14/11091,0.12809568246261,0.444844312425286,0.410382689168212,3306,1
R-HSA-4839735,Signaling by AXIN mutants,1/108,14/11091,0.12809568246261,0.444844312425286,0.410382689168212,5526,1
R-HSA-4839744,Signaling by APC mutants,1/108,14/11091,0.12809568246261,0.444844312425286,0.410382689168212,5526,1
R-HSA-4839748,Signaling by AMER1 mutants,1/108,14/11091,0.12809568246261,0.444844312425286,0.410382689168212,5526,1
R-HSA-5358565,Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha),1/108,14/11091,0.12809568246261,0.444844312425286,0.410382689168212,9156,1
R-HSA-5358606,Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta),1/108,14/11091,0.12809568246261,0.444844312425286,0.410382689168212,9156,1
R-HSA-5467337,APC truncation mutants have impaired AXIN binding,1/108,14/11091,0.12809568246261,0.444844312425286,0.410382689168212,5526,1
R-HSA-5467340,AXIN missense mutants destabilize the destruction complex,1/108,14/11091,0.12809568246261,0.444844312425286,0.410382689168212,5526,1
R-HSA-5467348,Truncations of AMER1 destabilize the destruction complex,1/108,14/11091,0.12809568246261,0.444844312425286,0.410382689168212,5526,1
R-HSA-5660526,Response to metal ions,1/108,14/11091,0.12809568246261,0.444844312425286,0.410382689168212,4494,1
R-HSA-5334118,DNA methylation,2/108,64/11091,0.128603163404924,0.444844312425286,0.410382689168212,8347/8339,2
R-HSA-5625886,Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3,2/108,66/11091,0.13517742411056,0.444844312425286,0.410382689168212,8347/8339,2
R-HSA-193807,Synthesis of bile acids and bile salts via 27-hydroxycholesterol,1/108,15/11091,0.136596690523821,0.444844312425286,0.410382689168212,9420,1
R-HSA-2032785,YAP1- and WWTR1 (TAZ)-stimulated gene expression,1/108,15/11091,0.136596690523821,0.444844312425286,0.410382689168212,860,1
R-HSA-3772470,Negative regulation of TCF-dependent signaling by WNT ligand antagonists,1/108,15/11091,0.136596690523821,0.444844312425286,0.410382689168212,6422,1
R-HSA-4839743,Signaling by CTNNB1 phospho-site mutants,1/108,15/11091,0.136596690523821,0.444844312425286,0.410382689168212,5526,1
R-HSA-5339716,Signaling by GSK3beta mutants,1/108,15/11091,0.136596690523821,0.444844312425286,0.410382689168212,5526,1
R-HSA-5358508,Mismatch Repair,1/108,15/11091,0.136596690523821,0.444844312425286,0.410382689168212,9156,1
R-HSA-5358747,CTNNB1 S33 mutants aren't phosphorylated,1/108,15/11091,0.136596690523821,0.444844312425286,0.410382689168212,5526,1
R-HSA-5358749,CTNNB1 S37 mutants aren't phosphorylated,1/108,15/11091,0.136596690523821,0.444844312425286,0.410382689168212,5526,1
R-HSA-5358751,CTNNB1 S45 mutants aren't phosphorylated,1/108,15/11091,0.136596690523821,0.444844312425286,0.410382689168212,5526,1
R-HSA-5358752,CTNNB1 T41 mutants aren't phosphorylated,1/108,15/11091,0.136596690523821,0.444844312425286,0.410382689168212,5526,1
R-HSA-5637810,Constitutive Signaling by EGFRvIII,1/108,15/11091,0.136596690523821,0.444844312425286,0.410382689168212,5295,1
R-HSA-5637812,Signaling by EGFRvIII in Cancer,1/108,15/11091,0.136596690523821,0.444844312425286,0.410382689168212,5295,1
R-HSA-427359,SIRT1 negatively regulates rRNA expression,2/108,67/11091,0.138492694355135,0.444844312425286,0.410382689168212,8347/8339,2
R-HSA-9670095,Inhibition of DNA recombination at telomere,2/108,67/11091,0.138492694355135,0.444844312425286,0.410382689168212,8347/8339,2
R-HSA-397014,Muscle contraction,4/108,205/11091,0.139590317652896,0.444844312425286,0.410382689168212,1193/56660/4634/7136,4
R-HSA-68616,Assembly of the ORC complex at the origin of replication,2/108,68/11091,0.141825835374631,0.444844312425286,0.410382689168212,8347/8339,2
R-HSA-9609690,HCMV Early Events,3/108,135/11091,0.14448025868049,0.444844312425286,0.410382689168212,92815/8347/8339,3
R-HSA-1963642,PI3K events in ERBB2 signaling,1/108,16/11091,0.145015574364867,0.444844312425286,0.410382689168212,5295,1
R-HSA-2730905,Role of LAT2/NTAL/LAB on calcium mobilization,1/108,16/11091,0.145015574364867,0.444844312425286,0.410382689168212,5295,1
R-HSA-391160,Signal regulatory protein family interactions,1/108,16/11091,0.145015574364867,0.444844312425286,0.410382689168212,6441,1
R-HSA-399954,Sema3A PAK dependent Axon repulsion,1/108,16/11091,0.145015574364867,0.444844312425286,0.410382689168212,3984,1
R-HSA-418457,cGMP effects,1/108,16/11091,0.145015574364867,0.444844312425286,0.410382689168212,5153,1
R-HSA-9651496,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),1/108,16/11091,0.145015574364867,0.444844312425286,0.410382689168212,2157,1
R-HSA-9665348,Signaling by ERBB2 ECD mutants,1/108,16/11091,0.145015574364867,0.444844312425286,0.410382689168212,5295,1
R-HSA-9703648,Signaling by FLT3 ITD and TKD mutants,1/108,16/11091,0.145015574364867,0.444844312425286,0.410382689168212,5295,1
R-HSA-5685942,HDR through Homologous Recombination (HRR),2/108,70/11091,0.148543128005243,0.444844312425286,0.410382689168212,675/9156,2
R-HSA-9821002,Chromatin modifications during the maternal to zygotic transition (MZT),2/108,70/11091,0.148543128005243,0.444844312425286,0.410382689168212,8347/8339,2
R-HSA-202733,Cell surface interactions at the vascular wall,3/108,137/11091,0.149040459101561,0.444844312425286,0.410382689168212,2886/5295/5627,3
R-HSA-180292,GAB1 signalosome,1/108,17/11091,0.153353120005372,0.444844312425286,0.410382689168212,5295,1
R-HSA-196299,Beta-catenin phosphorylation cascade,1/108,17/11091,0.153353120005372,0.444844312425286,0.410382689168212,5526,1
R-HSA-2022377,Metabolism of Angiotensinogen to Angiotensins,1/108,17/11091,0.153353120005372,0.444844312425286,0.410382689168212,290,1
R-HSA-432142,Platelet sensitization by LDL,1/108,17/11091,0.153353120005372,0.444844312425286,0.410382689168212,5526,1
R-HSA-9034015,Signaling by NTRK3 (TRKC),1/108,17/11091,0.153353120005372,0.444844312425286,0.410382689168212,5295,1
R-HSA-9754189,Germ layer formation at gastrulation,1/108,17/11091,0.153353120005372,0.444844312425286,0.410382689168212,5460,1
R-HSA-9834899,Specification of the neural plate border,1/108,17/11091,0.153353120005372,0.444844312425286,0.410382689168212,5460,1
R-HSA-212300,PRC2 methylates histones and DNA,2/108,72/11091,0.155324205735823,0.444844312425286,0.410382689168212,8347/8339,2
R-HSA-9710421,Defective pyroptosis,2/108,72/11091,0.155324205735823,0.444844312425286,0.410382689168212,8347/8339,2
R-HSA-3214847,HATs acetylate histones,3/108,141/11091,0.158298889574168,0.444844312425286,0.410382689168212,92815/8347/8339,3
R-HSA-68867,Assembly of the pre-replicative complex,3/108,141/11091,0.158298889574168,0.444844312425286,0.410382689168212,8347/8339/4173,3
R-HSA-2299718,Condensation of Prophase Chromosomes,2/108,73/11091,0.158737117575314,0.444844312425286,0.410382689168212,8347/8339,2
R-HSA-606279,Deposition of new CENPA-containing nucleosomes at the centromere,2/108,73/11091,0.158737117575314,0.444844312425286,0.410382689168212,8347/8339,2
R-HSA-774815,Nucleosome assembly,2/108,73/11091,0.158737117575314,0.444844312425286,0.410382689168212,8347/8339,2
R-HSA-1839117,Signaling by cytosolic FGFR1 fusion mutants,1/108,18/11091,0.161610106012183,0.444844312425286,0.410382689168212,5295,1
R-HSA-209776,Metabolism of amine-derived hormones,1/108,18/11091,0.161610106012183,0.444844312425286,0.410382689168212,1734,1
R-HSA-5654710,PI-3K cascade:FGFR3,1/108,18/11091,0.161610106012183,0.444844312425286,0.410382689168212,5295,1
R-HSA-73780,RNA Polymerase III Chain Elongation,1/108,18/11091,0.161610106012183,0.444844312425286,0.410382689168212,661,1
R-HSA-174824,"Plasma lipoprotein assembly, remodeling, and clearance",2/108,75/11091,0.165604684388129,0.448843663891293,0.41407221506234,23491/8029,2
R-HSA-427389,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,2/108,75/11091,0.165604684388129,0.448843663891293,0.41407221506234,8347/8339,2
R-HSA-1236382,Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants,1/108,19/11091,0.169787303569366,0.448843663891293,0.41407221506234,5295,1
R-HSA-5576886,Phase 4 - resting membrane potential,1/108,19/11091,0.169787303569366,0.448843663891293,0.41407221506234,56660,1
R-HSA-5637815,Signaling by Ligand-Responsive EGFR Variants in Cancer,1/108,19/11091,0.169787303569366,0.448843663891293,0.41407221506234,5295,1
R-HSA-8964038,LDL clearance,1/108,19/11091,0.169787303569366,0.448843663891293,0.41407221506234,23491,1
R-HSA-9671793,Diseases of hemostasis,1/108,19/11091,0.169787303569366,0.448843663891293,0.41407221506234,2157,1
R-HSA-9703465,Signaling by FLT3 fusion proteins,1/108,19/11091,0.169787303569366,0.448843663891293,0.41407221506234,5295,1
R-HSA-422356,Regulation of insulin secretion,2/108,78/11091,0.176001684499468,0.454501648212412,0.419291881260416,150/6616,2
R-HSA-5627117,RHO GTPases Activate ROCKs,1/108,20/11091,0.177885476547555,0.454501648212412,0.419291881260416,3984,1
R-HSA-5654720,PI-3K cascade:FGFR4,1/108,20/11091,0.177885476547555,0.454501648212412,0.419291881260416,5295,1
R-HSA-9603798,Class I peroxisomal membrane protein import,1/108,20/11091,0.177885476547555,0.454501648212412,0.419291881260416,5193,1
R-HSA-9669938,Signaling by KIT in disease,1/108,20/11091,0.177885476547555,0.454501648212412,0.419291881260416,5295,1
R-HSA-9670439,"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",1/108,20/11091,0.177885476547555,0.454501648212412,0.419291881260416,5295,1
R-HSA-9671555,Signaling by PDGFR in disease,1/108,20/11091,0.177885476547555,0.454501648212412,0.419291881260416,5295,1
R-HSA-2559586,DNA Damage/Telomere Stress Induced Senescence,2/108,79/11091,0.179490604139358,0.45641896481151,0.421060665349471,8347/8339,2
R-HSA-389513,CTLA4 inhibitory signaling,1/108,21/11091,0.185905381572653,0.466072646759609,0.429966486661733,5526,1
R-HSA-416572,Sema4D induced cell migration and growth-cone collapse,1/108,21/11091,0.185905381572653,0.466072646759609,0.429966486661733,3984,1
R-HSA-5654689,PI-3K cascade:FGFR1,1/108,21/11091,0.185905381572653,0.466072646759609,0.429966486661733,5295,1
R-HSA-1500931,Cell-Cell communication,3/108,153/11091,0.187069163246858,0.466798753148701,0.43063634234889,51208/5295/6441,3
R-HSA-201681,TCF dependent signaling in response to WNT,4/108,232/11091,0.190052575343953,0.468392344625068,0.432106479961624,8347/8339/5526/6422,4
R-HSA-196741,"Cobalamin (Cbl, vitamin B12) transport and metabolism",1/108,22/11091,0.193847768093895,0.468392344625068,0.432106479961624,8029,1
R-HSA-3296482,Defects in vitamin and cofactor metabolism,1/108,22/11091,0.193847768093895,0.468392344625068,0.432106479961624,8029,1
R-HSA-5365859,RA biosynthesis pathway,1/108,22/11091,0.193847768093895,0.468392344625068,0.432106479961624,8608,1
R-HSA-5655332,Signaling by FGFR3 in disease,1/108,22/11091,0.193847768093895,0.468392344625068,0.432106479961624,5295,1
R-HSA-5686938,Regulation of TLR by endogenous ligand,1/108,22/11091,0.193847768093895,0.468392344625068,0.432106479961624,6441,1
R-HSA-912631,Regulation of signaling by CBL,1/108,22/11091,0.193847768093895,0.468392344625068,0.432106479961624,5295,1
R-HSA-381340,Transcriptional regulation of white adipocyte differentiation,2/108,84/11091,0.197085415754943,0.470400578428395,0.433959137994262,1050/1959,2
R-HSA-69002,DNA Replication Pre-Initiation,3/108,158/11091,0.199441527328957,0.470400578428395,0.433959137994262,8347/8339/4173,3
R-HSA-373753,Nephrin family interactions,1/108,23/11091,0.201713378451277,0.470400578428395,0.433959137994262,5295,1
R-HSA-5654695,PI-3K cascade:FGFR2,1/108,23/11091,0.201713378451277,0.470400578428395,0.433959137994262,5295,1
R-HSA-73980,RNA Polymerase III Transcription Termination,1/108,23/11091,0.201713378451277,0.470400578428395,0.433959137994262,661,1
R-HSA-9637690,Response of Mtb to phagocytosis,1/108,23/11091,0.201713378451277,0.470400578428395,0.433959137994262,4843,1
R-HSA-2029480,Fcgamma receptor (FCGR) dependent phagocytosis,2/108,86/11091,0.20418387682144,0.470400578428395,0.433959137994262,3984/5295,2
R-HSA-9609646,HCMV Infection,3/108,160/11091,0.204445678175317,0.470400578428395,0.433959137994262,92815/8347/8339,3
R-HSA-156584,Cytosolic sulfonation of small molecules,1/108,24/11091,0.209502947942356,0.470400578428395,0.433959137994262,6820,1
R-HSA-193368,Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol,1/108,24/11091,0.209502947942356,0.470400578428395,0.433959137994262,9420,1
R-HSA-202040,G-protein activation,1/108,24/11091,0.209502947942356,0.470400578428395,0.433959137994262,5443,1
R-HSA-3371571,HSF1-dependent transactivation,1/108,24/11091,0.209502947942356,0.470400578428395,0.433959137994262,3306,1
R-HSA-449836,Other interleukin signaling,1/108,24/11091,0.209502947942356,0.470400578428395,0.433959137994262,6616,1
R-HSA-452723,Transcriptional regulation of pluripotent stem cells,1/108,24/11091,0.209502947942356,0.470400578428395,0.433959137994262,5460,1
R-HSA-5627123,RHO GTPases activate PAKs,1/108,24/11091,0.209502947942356,0.470400578428395,0.433959137994262,3984,1
R-HSA-8940973,RUNX2 regulates osteoblast differentiation,1/108,24/11091,0.209502947942356,0.470400578428395,0.433959137994262,860,1
R-HSA-2980736,Peptide hormone metabolism,2/108,88/11091,0.211311046555766,0.470400578428395,0.433959137994262,290/5443,2
R-HSA-1643713,Signaling by EGFR in Cancer,1/108,25/11091,0.217217204888432,0.470400578428395,0.433959137994262,5295,1
R-HSA-2029485,Role of phospholipids in phagocytosis,1/108,25/11091,0.217217204888432,0.470400578428395,0.433959137994262,5295,1
R-HSA-400685,Sema4D in semaphorin signaling,1/108,25/11091,0.217217204888432,0.470400578428395,0.433959137994262,3984,1
R-HSA-5654708,Downstream signaling of activated FGFR3,1/108,25/11091,0.217217204888432,0.470400578428395,0.433959137994262,5295,1
R-HSA-9006115,Signaling by NTRK2 (TRKB),1/108,25/11091,0.217217204888432,0.470400578428395,0.433959137994262,5295,1
R-HSA-9006335,Signaling by Erythropoietin,1/108,25/11091,0.217217204888432,0.470400578428395,0.433959137994262,5295,1
R-HSA-9664565,Signaling by ERBB2 KD Mutants,1/108,25/11091,0.217217204888432,0.470400578428395,0.433959137994262,5295,1
R-HSA-201722,Formation of the beta-catenin:TCF transactivating complex,2/108,90/11091,0.218463189981727,0.470400578428395,0.433959137994262,8347/8339,2
R-HSA-5250924,B-WICH complex positively regulates rRNA expression,2/108,90/11091,0.218463189981727,0.470400578428395,0.433959137994262,8347/8339,2
R-HSA-73772,RNA Polymerase I Promoter Escape,2/108,90/11091,0.218463189981727,0.470400578428395,0.433959137994262,8347/8339,2
R-HSA-73884,Base Excision Repair,2/108,91/11091,0.222047495691939,0.476198243773074,0.439307664273208,8347/8339,2
R-HSA-1227990,Signaling by ERBB2 in Cancer,1/108,26/11091,0.224856870700112,0.476200028812169,0.439309311027193,5295,1
R-HSA-5223345,Miscellaneous transport and binding events,1/108,26/11091,0.224856870700112,0.476200028812169,0.439309311027193,93380,1
R-HSA-111885,Opioid Signalling,2/108,92/11091,0.225636703573799,0.476200028812169,0.439309311027193,5153/5443,2
R-HSA-1912408,Pre-NOTCH Transcription and Translation,2/108,92/11091,0.225636703573799,0.476200028812169,0.439309311027193,8347/8339,2
R-HSA-5668914,Diseases of metabolism,4/108,250/11091,0.226507129809534,0.476200028812169,0.439309311027193,8029/9420/5443/6441,4
R-HSA-73894,DNA Repair,5/108,335/11091,0.227765753445316,0.476360964054767,0.439457778785001,675/9156/8347/8339/7468,5
R-HSA-5654716,Downstream signaling of activated FGFR4,1/108,27/11091,0.232422659942262,0.476360964054767,0.439457778785001,5295,1
R-HSA-76066,RNA Polymerase III Transcription Initiation From Type 2 Promoter,1/108,27/11091,0.232422659942262,0.476360964054767,0.439457778785001,661,1
R-HSA-912526,Interleukin receptor SHC signaling,1/108,27/11091,0.232422659942262,0.476360964054767,0.439457778785001,5295,1
R-HSA-9635486,Infection with Mycobacterium tuberculosis,1/108,27/11091,0.232422659942262,0.476360964054767,0.439457778785001,4843,1
R-HSA-5625740,RHO GTPases activate PKNs,2/108,94/11091,0.232828111644746,0.476360964054767,0.439457778785001,8347/8339,2
R-HSA-8936459,RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function,2/108,94/11091,0.232828111644746,0.476360964054767,0.439457778785001,8347/8339,2
R-HSA-3295583,TRP channels,1/108,28/11091,0.239915280398357,0.479830560796714,0.442658589499039,79054,1
R-HSA-400042,"Adrenaline,noradrenaline inhibits insulin secretion",1/108,28/11091,0.239915280398357,0.479830560796714,0.442658589499039,150,1
R-HSA-76061,RNA Polymerase III Transcription Initiation From Type 1 Promoter,1/108,28/11091,0.239915280398357,0.479830560796714,0.442658589499039,661,1
R-HSA-76071,RNA Polymerase III Transcription Initiation From Type 3 Promoter,1/108,28/11091,0.239915280398357,0.479830560796714,0.442658589499039,661,1
R-HSA-9619665,EGR2 and SOX10-mediated initiation of Schwann cell myelination,1/108,28/11091,0.239915280398357,0.479830560796714,0.442658589499039,1959,1
R-HSA-9682385,FLT3 signaling in disease,1/108,28/11091,0.239915280398357,0.479830560796714,0.442658589499039,5295,1
R-HSA-1614635,Sulfur amino acid metabolism,1/108,29/11091,0.247335433134231,0.48736945126819,0.449613450016781,875,1
R-HSA-420029,Tight junction interactions,1/108,29/11091,0.247335433134231,0.48736945126819,0.449613450016781,51208,1
R-HSA-9615017,"FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes",1/108,29/11091,0.247335433134231,0.48736945126819,0.449613450016781,5443,1
R-HSA-9753281,Paracetamol ADME,1/108,29/11091,0.247335433134231,0.48736945126819,0.449613450016781,55748,1
R-HSA-201556,Signaling by ALK,1/108,30/11091,0.254683812561234,0.492757811259779,0.454584379399914,5295,1
R-HSA-2424491,DAP12 signaling,1/108,30/11091,0.254683812561234,0.492757811259779,0.454584379399914,5295,1
R-HSA-5654696,Downstream signaling of activated FGFR2,1/108,30/11091,0.254683812561234,0.492757811259779,0.454584379399914,5295,1
R-HSA-9843743,Transcriptional regulation of brown and beige adipocyte differentiation,1/108,30/11091,0.254683812561234,0.492757811259779,0.454584379399914,1734,1
R-HSA-9844594,Transcriptional regulation of brown and beige adipocyte differentiation by EBF2,1/108,30/11091,0.254683812561234,0.492757811259779,0.454584379399914,1734,1
R-HSA-5668541,TNFR2 non-canonical NF-kB pathway,2/108,102/11091,0.261707454385773,0.497819326940774,0.459253784759082,9020/115650,2
R-HSA-1839124,FGFR1 mutant receptor activation,1/108,31/11091,0.261961106498797,0.497819326940774,0.459253784759082,5295,1
R-HSA-4641262,Disassembly of the destruction complex and recruitment of AXIN to the membrane,1/108,31/11091,0.261961106498797,0.497819326940774,0.459253784759082,5526,1
R-HSA-5654687,Downstream signaling of activated FGFR1,1/108,31/11091,0.261961106498797,0.497819326940774,0.459253784759082,5295,1
R-HSA-9680350,Signaling by CSF1 (M-CSF) in myeloid cells,1/108,31/11091,0.261961106498797,0.497819326940774,0.459253784759082,5295,1
R-HSA-3247509,Chromatin modifying enzymes,4/108,270/11091,0.26890941490321,0.502572412553319,0.463638653804363,92815/8347/8339/7468,4
R-HSA-4839726,Chromatin organization,4/108,270/11091,0.26890941490321,0.502572412553319,0.463638653804363,92815/8347/8339/7468,4
R-HSA-2187338,Visual phototransduction,2/108,104/11091,0.26894043200606,0.502572412553319,0.463638653804363,3292/8608,2
R-HSA-9645723,Diseases of programmed cell death,2/108,104/11091,0.26894043200606,0.502572412553319,0.463638653804363,8347/8339,2
R-HSA-8941326,RUNX2 regulates bone development,1/108,32/11091,0.269167996236422,0.502572412553319,0.463638653804363,860,1
R-HSA-5250913,Positive epigenetic regulation of rRNA expression,2/108,105/11091,0.272556915503812,0.503573220552136,0.464561930255076,8347/8339,2
R-HSA-5578749,Transcriptional regulation by small RNAs,2/108,105/11091,0.272556915503812,0.503573220552136,0.464561930255076,8347/8339,2
R-HSA-427413,NoRC negatively regulates rRNA expression,2/108,106/11091,0.276172943199753,0.503573220552136,0.464561930255076,8347/8339,2
R-HSA-8856825,Cargo recognition for clathrin-mediated endocytosis,2/108,106/11091,0.276172943199753,0.503573220552136,0.464561930255076,157/9185,2
R-HSA-352230,Amino acid transport across the plasma membrane,1/108,33/11091,0.276305156595086,0.503573220552136,0.464561930255076,120103,1
R-HSA-5694530,Cargo concentration in the ER,1/108,33/11091,0.276305156595086,0.503573220552136,0.464561930255076,2157,1
R-HSA-68962,Activation of the pre-replicative complex,1/108,33/11091,0.276305156595086,0.503573220552136,0.464561930255076,4173,1
R-HSA-192105,Synthesis of bile acids and bile salts,1/108,34/11091,0.28337325598808,0.50652015147879,0.467280565527447,9420,1
R-HSA-4791275,Signaling by WNT in cancer,1/108,34/11091,0.28337325598808,0.50652015147879,0.467280565527447,5526,1
R-HSA-5579029,Metabolic disorders of biological oxidation enzymes,1/108,34/11091,0.28337325598808,0.50652015147879,0.467280565527447,9420,1
R-HSA-163685,Integration of energy metabolism,2/108,108/11091,0.283402313190446,0.50652015147879,0.467280565527447,150/6616,2
R-HSA-1912422,Pre-NOTCH Expression and Processing,2/108,108/11091,0.283402313190446,0.50652015147879,0.467280565527447,8347/8339,2
R-HSA-156580,Phase II - Conjugation of compounds,2/108,109/11091,0.28701501232686,0.50652015147879,0.467280565527447,55748/6820,2
R-HSA-2672351,Stimuli-sensing channels,2/108,109/11091,0.28701501232686,0.50652015147879,0.467280565527447,1193/79054,2
R-HSA-5250941,Negative epigenetic regulation of rRNA expression,2/108,109/11091,0.28701501232686,0.50652015147879,0.467280565527447,8347/8339,2
R-HSA-73854,RNA Polymerase I Promoter Clearance,2/108,109/11091,0.28701501232686,0.50652015147879,0.467280565527447,8347/8339,2
R-HSA-114604,GPVI-mediated activation cascade,1/108,35/11091,0.290372956481278,0.50652015147879,0.467280565527447,5295,1
R-HSA-2559582,Senescence-Associated Secretory Phenotype (SASP),2/108,110/11091,0.290625969164507,0.50652015147879,0.467280565527447,8347/8339,2
R-HSA-5673001,RAF/MAP kinase cascade,4/108,280/11091,0.290645681017708,0.50652015147879,0.467280565527447,22866/4902/5295/5526,4
R-HSA-73864,RNA Polymerase I Transcription,2/108,111/11091,0.294234877560105,0.50652015147879,0.467280565527447,8347/8339,2
R-HSA-1222556,ROS and RNS production in phagocytes,1/108,36/11091,0.297304913852843,0.50652015147879,0.467280565527447,4843,1
R-HSA-1266695,Interleukin-7 signaling,1/108,36/11091,0.297304913852843,0.50652015147879,0.467280565527447,5295,1
R-HSA-156590,Glutathione conjugation,1/108,36/11091,0.297304913852843,0.50652015147879,0.467280565527447,55748,1
R-HSA-5673000,RAF activation,1/108,36/11091,0.297304913852843,0.50652015147879,0.467280565527447,5526,1
R-HSA-6802948,Signaling by high-kinase activity BRAF mutants,1/108,36/11091,0.297304913852843,0.50652015147879,0.467280565527447,22866,1
R-HSA-76046,RNA Polymerase III Transcription Initiation,1/108,36/11091,0.297304913852843,0.50652015147879,0.467280565527447,661,1
R-HSA-157579,Telomere Maintenance,2/108,112/11091,0.297841437386405,0.50652015147879,0.467280565527447,8347/8339,2
R-HSA-983705,Signaling by the B Cell Receptor (BCR),2/108,112/11091,0.297841437386405,0.50652015147879,0.467280565527447,933/5295,2
R-HSA-5684996,MAPK1/MAPK3 signaling,4/108,286/11091,0.303808981450075,0.507583316457411,0.468261368228008,22866/4902/5295/5526,4
R-HSA-111933,Calmodulin induced events,1/108,37/11091,0.304169777652381,0.507583316457411,0.468261368228008,5153,1
R-HSA-111997,CaM pathway,1/108,37/11091,0.304169777652381,0.507583316457411,0.468261368228008,5153,1
R-HSA-176187,Activation of ATR in response to replication stress,1/108,37/11091,0.304169777652381,0.507583316457411,0.468261368228008,4173,1
R-HSA-5685938,HDR through Single Strand Annealing (SSA),1/108,37/11091,0.304169777652381,0.507583316457411,0.468261368228008,9156,1
R-HSA-5689901,Metalloprotease DUBs,1/108,37/11091,0.304169777652381,0.507583316457411,0.468261368228008,92815,1
R-HSA-187037,Signaling by NTRK1 (TRKA),2/108,115/11091,0.308644112613953,0.510944658869522,0.47136231096183,1959/5295,2
R-HSA-5655302,Signaling by FGFR1 in disease,1/108,38/11091,0.310968191259541,0.510944658869522,0.47136231096183,5295,1
R-HSA-9013407,RHOH GTPase cycle,1/108,38/11091,0.310968191259541,0.510944658869522,0.47136231096183,55717,1
R-HSA-9013424,RHOV GTPase cycle,1/108,38/11091,0.310968191259541,0.510944658869522,0.47136231096183,5295,1
R-HSA-9607240,FLT3 Signaling,1/108,38/11091,0.310968191259541,0.510944658869522,0.47136231096183,5295,1
R-HSA-449147,Signaling by Interleukins,6/108,473/11091,0.313351513870881,0.511000671376699,0.471413984238705,3598/9173/4843/5295/5443/6616,6
R-HSA-9816359,Maternal to zygotic transition (MZT),2/108,117/11091,0.315828913870824,0.511000671376699,0.471413984238705,8347/8339,2
R-HSA-111996,Ca-dependent events,1/108,39/11091,0.317700791942067,0.511000671376699,0.471413984238705,5153,1
R-HSA-5689896,Ovarian tumor domain proteases,1/108,39/11091,0.317700791942067,0.511000671376699,0.471413984238705,79931,1
R-HSA-76009,Platelet Aggregation (Plug Formation),1/108,39/11091,0.317700791942067,0.511000671376699,0.471413984238705,150,1
R-HSA-9031628,NGF-stimulated transcription,1/108,39/11091,0.317700791942067,0.511000671376699,0.471413984238705,1959,1
R-HSA-9856649,Transcriptional and post-translational regulation of MITF-M expression and activity,1/108,39/11091,0.317700791942067,0.511000671376699,0.471413984238705,5443,1
R-HSA-5654741,Signaling by FGFR3,1/108,40/11091,0.324368210913318,0.515513763772951,0.475577452090955,5295,1
R-HSA-5674135,MAP2K and MAPK activation,1/108,40/11091,0.324368210913318,0.515513763772951,0.475577452090955,22866,1
R-HSA-9013420,RHOU GTPase cycle,1/108,40/11091,0.324368210913318,0.515513763772951,0.475577452090955,5295,1
R-HSA-9692916,SARS-CoV-1 activates/modulates innate immune responses,1/108,40/11091,0.324368210913318,0.515513763772951,0.475577452090955,6441,1
R-HSA-69239,Synthesis of DNA,2/108,120/11091,0.326575270209274,0.516580299146131,0.476561364085136,51659/4173,2
R-HSA-5688426,Deubiquitination,4/108,297/11091,0.328108809918282,0.516580299146131,0.476561364085136,92815/8347/8339/79931,4
R-HSA-9006931,Signaling by Nuclear Receptors,4/108,298/11091,0.330325719274857,0.516580299146131,0.476561364085136,8347/8339/5295/8608,4
R-HSA-5654743,Signaling by FGFR4,1/108,41/11091,0.330971073389235,0.516580299146131,0.476561364085136,5295,1
R-HSA-74158,RNA Polymerase III Transcription,1/108,41/11091,0.330971073389235,0.516580299146131,0.476561364085136,661,1
R-HSA-749476,RNA Polymerase III Abortive And Retractive Initiation,1/108,41/11091,0.330971073389235,0.516580299146131,0.476561364085136,661,1
R-HSA-375280,Amine ligand-binding receptors,1/108,42/11091,0.337509998644797,0.516580299146131,0.476561364085136,150,1
R-HSA-3928662,EPHB-mediated forward signaling,1/108,42/11091,0.337509998644797,0.516580299146131,0.476561364085136,3984,1
R-HSA-419037,NCAM1 interactions,1/108,42/11091,0.337509998644797,0.516580299146131,0.476561364085136,4902,1
R-HSA-9035034,RHOF GTPase cycle,1/108,42/11091,0.337509998644797,0.516580299146131,0.476561364085136,5295,1
R-HSA-9696264,RND3 GTPase cycle,1/108,42/11091,0.337509998644797,0.516580299146131,0.476561364085136,5295,1
R-HSA-2559580,Oxidative Stress Induced Senescence,2/108,124/11091,0.340835564286023,0.516580299146131,0.476561364085136,8347/8339,2
R-HSA-1483257,Phospholipid metabolism,3/108,212/11091,0.340961733828308,0.516580299146131,0.476561364085136,9108/5295/57664,3
R-HSA-1489509,DAG and IP3 signaling,1/108,43/11091,0.343985600069936,0.516580299146131,0.476561364085136,5153,1
R-HSA-5362517,Signaling by Retinoic Acid,1/108,43/11091,0.343985600069936,0.516580299146131,0.476561364085136,8608,1
R-HSA-5655253,Signaling by FGFR2 in disease,1/108,43/11091,0.343985600069936,0.516580299146131,0.476561364085136,5295,1
R-HSA-5675221,Negative regulation of MAPK pathway,1/108,43/11091,0.343985600069936,0.516580299146131,0.476561364085136,5526,1
R-HSA-9656223,Signaling by RAF1 mutants,1/108,43/11091,0.343985600069936,0.516580299146131,0.476561364085136,22866,1
R-HSA-9696270,RND2 GTPase cycle,1/108,43/11091,0.343985600069936,0.516580299146131,0.476561364085136,5295,1
R-HSA-9758941,Gastrulation,2/108,125/11091,0.344386866097421,0.516580299146131,0.476561364085136,9241/5460,2
R-HSA-109704,PI3K Cascade,1/108,44/11091,0.350398485224937,0.521205546267734,0.480828298153557,5295,1
R-HSA-451927,Interleukin-2 family signaling,1/108,44/11091,0.350398485224937,0.521205546267734,0.480828298153557,5295,1
R-HSA-6811438,Intra-Golgi traffic,1/108,44/11091,0.350398485224937,0.521205546267734,0.480828298153557,27333,1
R-HSA-416476,G alpha (q) signalling events,3/108,216/11091,0.351644473979198,0.521605969735811,0.481197701234693,8111/5295/6865,3
R-HSA-194068,Bile acid and bile salt metabolism,1/108,45/11091,0.356749255895319,0.525147404289778,0.484464784560647,9420,1
R-HSA-2172127,DAP12 interactions,1/108,45/11091,0.356749255895319,0.525147404289778,0.484464784560647,5295,1
R-HSA-9006925,Intracellular signaling by second messengers,4/108,310/11091,0.3569822242644,0.525147404289778,0.484464784560647,9173/5153/5295/5526,4
R-HSA-8939236,RUNX1 regulates transcription of genes involved in differentiation of HSCs,2/108,129/11091,0.358530250100329,0.525975696575757,0.485228909910219,8347/8339,2
R-HSA-5689880,Ub-specific processing proteases,3/108,219/11091,0.359645752332501,0.52616666231659,0.485405081734997,92815/8347/8339,3
R-HSA-8939211,ESR-mediated signaling,3/108,222/11091,0.367634315712395,0.531505359808322,0.490330195920155,8347/8339/5295,3
R-HSA-5576891,Cardiac conduction,2/108,132/11091,0.369066986263098,0.531505359808322,0.490330195920155,1193/56660,2
R-HSA-6802946,Signaling by moderate kinase activity BRAF mutants,1/108,47/11091,0.369266832376194,0.531505359808322,0.490330195920155,22866,1
R-HSA-6802949,Signaling by RAS mutants,1/108,47/11091,0.369266832376194,0.531505359808322,0.490330195920155,22866,1
R-HSA-6802955,Paradoxical activation of RAF signaling by kinase inactive BRAF,1/108,47/11091,0.369266832376194,0.531505359808322,0.490330195920155,22866,1
R-HSA-9649948,Signaling downstream of RAS mutants,1/108,47/11091,0.369266832376194,0.531505359808322,0.490330195920155,22866,1
R-HSA-418594,G alpha (i) signalling events,4/108,318/11091,0.374766781544069,0.534077797982657,0.492703350001741,150/29899/5153/5443,4
R-HSA-112399,IRS-mediated signalling,1/108,48/11091,0.375434813370704,0.534077797982657,0.492703350001741,5295,1
R-HSA-418597,G alpha (z) signalling events,1/108,48/11091,0.375434813370704,0.534077797982657,0.492703350001741,150,1
R-HSA-512988,"Interleukin-3, Interleukin-5 and GM-CSF signaling",1/108,48/11091,0.375434813370704,0.534077797982657,0.492703350001741,5295,1
R-HSA-166520,Signaling by NTRKs,2/108,134/11091,0.376054779103893,0.534077797982657,0.492703350001741,1959/5295,2
R-HSA-70268,Pyruvate metabolism,1/108,49/11091,0.381543030354854,0.540434955462843,0.498568025146088,10873,1
R-HSA-211000,Gene Silencing by RNA,2/108,137/11091,0.386477707898966,0.544668838059129,0.502473913289321,8347/8339,2
R-HSA-1483249,Inositol phosphate metabolism,1/108,50/11091,0.387592057045822,0.544668838059129,0.502473913289321,9108,1
R-HSA-381038,XBP1(S) activates chaperone genes,1/108,50/11091,0.387592057045822,0.544668838059129,0.502473913289321,5526,1
R-HSA-5683057,MAPK family signaling cascades,4/108,325/11091,0.390303694766805,0.547039824161348,0.504661221579955,22866/4902/5295/5526,4
R-HSA-195258,RHO GTPase Effectors,4/108,326/11091,0.392519938963759,0.547325610808147,0.504924868634364,8347/8339/3984/5526,4
R-HSA-112043,PLC beta mediated events,1/108,51/11091,0.393582461704735,0.547325610808147,0.504924868634364,5153,1
R-HSA-5620920,Cargo trafficking to the periciliary membrane,1/108,51/11091,0.393582461704735,0.547325610808147,0.504924868634364,192668,1
R-HSA-73886,Chromosome Maintenance,2/108,140/11091,0.396825944829526,0.549454411346731,0.506888753223477,8347/8339,2
R-HSA-2428928,IRS-related events triggered by IGF1R,1/108,52/11091,0.399514807188058,0.549454411346731,0.506888753223477,5295,1
R-HSA-381070,IRE1alpha activates chaperones,1/108,52/11091,0.399514807188058,0.549454411346731,0.506888753223477,5526,1
R-HSA-5654736,Signaling by FGFR1,1/108,52/11091,0.399514807188058,0.549454411346731,0.506888753223477,5295,1
R-HSA-68875,Mitotic Prophase,2/108,141/11091,0.400257988790034,0.549454411346731,0.506888753223477,8347/8339,2
R-HSA-195721,Signaling by WNT,4/108,331/11091,0.403584495480388,0.550834792959821,0.508162198117872,8347/8339/5526/6422,4
R-HSA-8878171,Transcriptional regulation by RUNX1,3/108,236/11091,0.404659929589545,0.550834792959821,0.508162198117872,8347/8339/860,3
R-HSA-177929,Signaling by EGFR,1/108,53/11091,0.40538965099852,0.550834792959821,0.508162198117872,5295,1
R-HSA-2428924,IGF1R signaling cascade,1/108,53/11091,0.40538965099852,0.550834792959821,0.508162198117872,5295,1
R-HSA-373076,Class A/1 (Rhodopsin-like receptors),4/108,334/11091,0.410207622013016,0.553110401030692,0.510261517213412,150/8111/5443/6865,4
R-HSA-2404192,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),1/108,54/11091,0.411207545335552,0.553110401030692,0.510261517213412,5295,1
R-HSA-74751,Insulin receptor signalling cascade,1/108,54/11091,0.411207545335552,0.553110401030692,0.510261517213412,5295,1
R-HSA-9013405,RHOD GTPase cycle,1/108,54/11091,0.411207545335552,0.553110401030692,0.510261517213412,5295,1
R-HSA-3371497,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,1/108,55/11091,0.416969037145261,0.555680989746204,0.512632965111814,3306,1
R-HSA-6794361,Neurexins and neuroligins,1/108,55/11091,0.416969037145261,0.555680989746204,0.512632965111814,57502,1
R-HSA-9013409,RHOJ GTPase cycle,1/108,55/11091,0.416969037145261,0.555680989746204,0.512632965111814,5295,1
R-HSA-8856828,Clathrin-mediated endocytosis,2/108,146/11091,0.417281042861849,0.555680989746204,0.512632965111814,157/9185,2
R-HSA-112040,G-protein mediated events,1/108,56/11091,0.422674668169936,0.560070155838079,0.516682107100771,5153,1
R-HSA-5578775,Ion homeostasis,1/108,56/11091,0.422674668169936,0.560070155838079,0.516682107100771,1193,1
R-HSA-5358351,Signaling by Hedgehog,2/108,149/11091,0.427380020105319,0.56350847095368,0.519854059543312,57758/7289,2
R-HSA-9018519,Estrogen-dependent gene expression,2/108,149/11091,0.427380020105319,0.56350847095368,0.519854059543312,8347/8339,2
R-HSA-1236394,Signaling by ERBB4,1/108,58/11091,0.433920489108048,0.57072300784162,0.526509693810129,5295,1
R-HSA-425407,SLC-mediated transmembrane transport,3/108,249/11091,0.438492146193984,0.575177861565015,0.530619434678547,6507/120103/6550,3
R-HSA-5676590,NIK-->noncanonical NF-kB signaling,1/108,59/11091,0.439461736926079,0.575177861565015,0.530619434678547,9020,1
R-HSA-5607761,Dectin-1 mediated noncanonical NF-kB signaling,1/108,60/11091,0.444949239864076,0.580936171362877,0.535931654243695,9020,1
R-HSA-198725,Nuclear Events (kinase and transcription factor activation),1/108,61/11091,0.450383514371798,0.585169821592555,0.539837328021517,1959,1
R-HSA-2029482,Regulation of actin dynamics for phagocytic cup formation,1/108,61/11091,0.450383514371798,0.585169821592555,0.539837328021517,3984,1
R-HSA-1226099,Signaling by FGFR in disease,1/108,63/11091,0.461094419360111,0.596185036170216,0.54999920545567,5295,1
R-HSA-375165,NCAM signaling for neurite out-growth,1/108,63/11091,0.461094419360111,0.596185036170216,0.54999920545567,4902,1
R-HSA-1834949,Cytosolic sensors of pathogen-associated DNA,1/108,64/11091,0.466372058343527,0.600102841338418,0.553613502358327,661,1
R-HSA-913709,O-linked glycosylation of mucins,1/108,64/11091,0.466372058343527,0.600102841338418,0.553613502358327,57452,1
R-HSA-69242,S Phase,2/108,162/11091,0.470056980537188,0.602472706987218,0.555799776995896,51659/4173,2
R-HSA-5358346,Hedgehog ligand biogenesis,1/108,65/11091,0.47159848599374,0.602472706987218,0.555799776995896,57758,1
R-HSA-9614085,FOXO-mediated transcription,1/108,65/11091,0.47159848599374,0.602472706987218,0.555799776995896,5443,1
R-HSA-9609507,Protein localization,2/108,164/11091,0.476456673426492,0.607226404796532,0.560185210811703,4843/5193,2
R-HSA-500792,GPCR ligand binding,5/108,468/11091,0.481466258874872,0.611245664614417,0.563893102778527,150/11211/8111/5443/6865,5
R-HSA-6802952,Signaling by BRAF and RAF1 fusions,1/108,67/11091,0.481899671915111,0.611245664614417,0.563893102778527,22866,1
R-HSA-1257604,PIP3 activates AKT signaling,3/108,268/11091,0.486592919679984,0.613852787622034,0.566298254695667,9173/5295/5526,3
R-HSA-204005,COPII-mediated vesicle transport,1/108,68/11091,0.4869754008187,0.613852787622034,0.566298254695667,2157,1
R-HSA-112315,Transmission across Chemical Synapses,3/108,270/11091,0.491546064990314,0.613852787622034,0.566298254695667,22999/6507/6616,3
R-HSA-3214841,PKMTs methylate histone lysines,1/108,69/11091,0.492001859742005,0.613852787622034,0.566298254695667,7468,1
R-HSA-3371453,Regulation of HSF1-mediated heat shock response,1/108,69/11091,0.492001859742005,0.613852787622034,0.566298254695667,3306,1
R-HSA-9662360,Sensory processing of sound by inner hair cells of the cochlea,1/108,69/11091,0.492001859742005,0.613852787622034,0.566298254695667,6616,1
R-HSA-9793380,Formation of paraxial mesoderm,1/108,69/11091,0.492001859742005,0.613852787622034,0.566298254695667,9241,1
R-HSA-9013026,RHOB GTPase cycle,1/108,70/11091,0.496979522520798,0.61861786719372,0.570694188540629,5295,1
R-HSA-68949,Orc1 removal from chromatin,1/108,71/11091,0.501908858476497,0.623300768433603,0.575014310323135,4173,1
R-HSA-8939902,Regulation of RUNX2 expression and activity,1/108,72/11091,0.50679033245876,0.627902639287651,0.57925967905898,860,1
R-HSA-5654738,Signaling by FGFR2,1/108,73/11091,0.511624404887696,0.632424611597291,0.583431338907022,5295,1
R-HSA-9013106,RHOC GTPase cycle,1/108,74/11091,0.516411531795677,0.635400364006662,0.586176562892013,5295,1
R-HSA-9013408,RHOG GTPase cycle,1/108,74/11091,0.516411531795677,0.635400364006662,0.586176562892013,5295,1
R-HSA-9833482,PKR-mediated signaling,1/108,75/11091,0.521152164868752,0.639759209287158,0.590197732991109,3306,1
R-HSA-9659379,Sensory processing of sound,1/108,76/11091,0.525846751487686,0.644041663519321,0.594148429976429,6616,1
R-HSA-9009391,Extra-nuclear estrogen signaling,1/108,77/11091,0.530495734768605,0.648248792600538,0.598029637171401,5295,1
R-HSA-2219530,Constitutive Signaling by Aberrant PI3K in Cancer,1/108,78/11091,0.53509955360327,0.650895584565253,0.600471384933054,5295,1
R-HSA-3214858,RMTs methylate histone arginines,1/108,78/11091,0.53509955360327,0.650895584565253,0.600471384933054,92815,1
R-HSA-6806834,Signaling by MET,1/108,79/11091,0.539658642698961,0.654791115062818,0.604065132760494,5295,1
R-HSA-9013149,RAC1 GTPase cycle,2/108,185/11091,0.540754460192327,0.654791115062818,0.604065132760494,152273/5295,2
R-HSA-983712,Ion channel transport,2/108,186/11091,0.54367931430984,0.656843334482929,0.605958368890224,1193/79054,2
R-HSA-212165,Epigenetic regulation of gene expression,2/108,187/11091,0.54659139427732,0.658870890618711,0.607828852374447,8347/8339,2
R-HSA-74752,Signaling by Insulin receptor,1/108,82/11091,0.553071816685201,0.665180968715985,0.613650095326396,5295,1
R-HSA-2467813,Separation of Sister Chromatids,2/108,190/11091,0.555250691919811,0.666300830303773,0.614683202409158,9700/5526,2
R-HSA-195253,Degradation of beta-catenin by the destruction complex,1/108,83/11091,0.557456251583738,0.667447619609229,0.615741151147485,5526,1
R-HSA-6802957,Oncogenic MAPK signaling,1/108,84/11091,0.56179806888288,0.671141317188944,0.619148701841959,22866,1
R-HSA-2559583,Cellular Senescence,2/108,195/11091,0.569424856753177,0.676821846279207,0.624389166289511,8347/8339,2
R-HSA-112316,Neuronal System,4/108,410/11091,0.569646014288724,0.676821846279207,0.624389166289511,57502/22999/6507/6616,4
R-HSA-6794362,Protein-protein interactions at synapses,1/108,86/11091,0.570355488437534,0.676821846279207,0.624389166289511,57502,1
R-HSA-421270,Cell-cell junction organization,1/108,88/11091,0.57874731192508,0.683741293292019,0.630772570984949,51208,1
R-HSA-9013404,RAC2 GTPase cycle,1/108,88/11091,0.57874731192508,0.683741293292019,0.630772570984949,5295,1
R-HSA-190236,Signaling by FGFR,1/108,89/11091,0.58288211973314,0.684428359061326,0.631406410488272,5295,1
R-HSA-3371556,Cellular response to heat stress,1/108,89/11091,0.58288211973314,0.684428359061326,0.631406410488272,3306,1
R-HSA-68886,M Phase,4/108,417/11091,0.583173976353752,0.684428359061326,0.631406410488272,9700/8347/8339/5526,4
R-HSA-375276,Peptide ligand-binding receptors,2/108,201/11091,0.586005194617224,0.686242925275433,0.633080404157112,5443/6865,2
R-HSA-69052,Switching of origins to a post-replicative state,1/108,91/11091,0.591031483546754,0.687605255368119,0.634337195963492,4173,1
R-HSA-9700206,Signaling by ALK in cancer,1/108,91/11091,0.591031483546754,0.687605255368119,0.634337195963492,5295,1
R-HSA-9725370,Signaling by ALK fusions and activated point mutants,1/108,91/11091,0.591031483546754,0.687605255368119,0.634337195963492,5295,1
R-HSA-2682334,EPH-Ephrin signaling,1/108,92/11091,0.595046810799204,0.689273312292353,0.635876030263791,3984,1
R-HSA-6804756,Regulation of TP53 Activity through Phosphorylation,1/108,92/11091,0.595046810799204,0.689273312292353,0.635876030263791,9156,1
R-HSA-9013423,RAC3 GTPase cycle,1/108,94/11091,0.60296065658261,0.696848605017904,0.642864472991088,5295,1
R-HSA-373080,Class B/2 (Secretin family receptors),1/108,95/11091,0.606859924481953,0.696848605017904,0.642864472991088,11211,1
R-HSA-381119,Unfolded Protein Response (UPR),1/108,95/11091,0.606859924481953,0.696848605017904,0.642864472991088,5526,1
R-HSA-6803157,Antimicrobial peptides,1/108,95/11091,0.606859924481953,0.696848605017904,0.642864472991088,1191,1
R-HSA-141424,Amplification of signal from the kinetochores,1/108,96/11091,0.610721249341534,0.696848605017904,0.642864472991088,5526,1
R-HSA-141444,Amplification  of signal from unattached  kinetochores via a MAD2  inhibitory signal,1/108,96/11091,0.610721249341534,0.696848605017904,0.642864472991088,5526,1
R-HSA-9692914,SARS-CoV-1-host interactions,1/108,96/11091,0.610721249341534,0.696848605017904,0.642864472991088,6441,1
R-HSA-202424,Downstream TCR signaling,1/108,98/11091,0.618331529644586,0.702529865596189,0.648105612259051,5295,1
R-HSA-5619102,SLC transporter disorders,1/108,98/11091,0.618331529644586,0.702529865596189,0.648105612259051,6507,1
R-HSA-4420097,VEGFA-VEGFR2 Pathway,1/108,99/11091,0.622081206238635,0.705289520448899,0.650651479538901,5295,1
R-HSA-5607764,CLEC7A (Dectin-1) signaling,1/108,101/11091,0.629471409430068,0.712156213211137,0.656986216800339,9020,1
R-HSA-5689603,UCH proteinases,1/108,102/11091,0.633112636707735,0.714761412266237,0.65938959381155,92815,1
R-HSA-382556,ABC-family proteins mediated transport,1/108,103/11091,0.636718409319944,0.717315676322468,0.661745981704938,10351,1
R-HSA-2219528,PI3K/AKT Signaling in Cancer,1/108,104/11091,0.640289069293865,0.719819711585103,0.664056031976795,5295,1
R-HSA-9012999,RHO GTPase cycle,4/108,449/11091,0.64184369774053,0.720051543263535,0.664269903897762,152273/2886/5295/55717,4
R-HSA-194138,Signaling by VEGF,1/108,108/11091,0.654227309594468,0.732405415772423,0.675666734834405,5295,1
R-HSA-9748784,Drug ADME,1/108,110/11091,0.660994409277263,0.738433084841127,0.681227446689626,55748,1
R-HSA-5173105,O-linked glycosylation,1/108,112/11091,0.667630272869427,0.74196142143294,0.684482446738845,57452,1
R-HSA-69618,Mitotic Spindle Checkpoint,1/108,112/11091,0.667630272869427,0.74196142143294,0.684482446738845,5526,1
R-HSA-5610787,Hedgehog 'off' state,1/108,113/11091,0.670899781069637,0.74196142143294,0.684482446738845,7289,1
R-HSA-157118,Signaling by NOTCH,2/108,235/11091,0.671099937363502,0.74196142143294,0.684482446738845,8347/8339,2
R-HSA-68882,Mitotic Anaphase,2/108,235/11091,0.671099937363502,0.74196142143294,0.684482446738845,9700/5526,2
R-HSA-2555396,Mitotic Metaphase and Anaphase,2/108,236/11091,0.673377202387211,0.74224615138453,0.684745118959117,9700/5526,2
R-HSA-9730414,MITF-M-regulated melanocyte development,1/108,114/11091,0.674137422137634,0.74224615138453,0.684745118959117,5443,1
R-HSA-446728,Cell junction organization,1/108,115/11091,0.677343503800123,0.744241627632234,0.686586007750612,51208,1
R-HSA-168179,Toll Like Receptor TLR1:TLR2 Cascade,1/108,116/11091,0.68051833083999,0.744665550550317,0.686977089803959,6441,1
R-HSA-181438,Toll Like Receptor 2 (TLR2) Cascade,1/108,116/11091,0.68051833083999,0.744665550550317,0.686977089803959,6441,1
R-HSA-9648025,EML4 and NUDC in mitotic spindle formation,1/108,117/11091,0.683662205124207,0.746575904982263,0.688739451077665,5526,1
R-HSA-2408522,Selenoamino acid metabolism,1/108,119/11091,0.689858288479523,0.750273576472638,0.692150667828099,875,1
R-HSA-373760,L1CAM interactions,1/108,119/11091,0.689858288479523,0.750273576472638,0.692150667828099,214,1
R-HSA-202403,TCR signaling,1/108,120/11091,0.692911086952382,0.750536552601566,0.692393271471581,5295,1
R-HSA-8878166,Transcriptional regulation by RUNX2,1/108,120/11091,0.692911086952382,0.750536552601566,0.692393271471581,860,1
R-HSA-9705671,SARS-CoV-2 activates/modulates innate and adaptive immune responses,1/108,126/11091,0.710612599472356,0.768123392976868,0.708617677731469,6441,1
R-HSA-196849,Metabolism of water-soluble vitamins and cofactors,1/108,127/11091,0.713462926809974,0.768123392976868,0.708617677731469,8029,1
R-HSA-2500257,Resolution of Sister Chromatid Cohesion,1/108,127/11091,0.713462926809974,0.768123392976868,0.708617677731469,5526,1
R-HSA-6809371,Formation of the cornified envelope,1/108,129/11091,0.719080399598139,0.772613548059167,0.712759985199469,7062,1
R-HSA-69206,G1/S Transition,1/108,131/11091,0.724588743406228,0.776968652568123,0.716777704320682,4173,1
R-HSA-2454202,Fc epsilon receptor (FCERI) signaling,1/108,134/11091,0.732651226335884,0.784039588904533,0.723300862620385,5295,1
R-HSA-5663220,RHO GTPases Activate Formins,1/108,140/11091,0.748081210357856,0.79895073266219,0.737056855678898,5526,1
R-HSA-9678108,SARS-CoV-1 Infection,1/108,142/11091,0.753025836233673,0.80262634041673,0.740447717948018,6441,1
R-HSA-5621481,C-type lectin receptors (CLRs),1/108,143/11091,0.75546196827192,0.803618906488457,0.741363390965105,9020,1
R-HSA-166016,Toll Like Receptor 4 (TLR4) Cascade,1/108,147/11091,0.764970696117829,0.810504666124843,0.747715718009908,6441,1
R-HSA-8980692,RHOA GTPase cycle,1/108,147/11091,0.764970696117829,0.810504666124843,0.747715718009908,5295,1
R-HSA-1169410,Antiviral mechanism by IFN-stimulated genes,1/108,149/11091,0.769586753735698,0.812172582005657,0.749254422193273,3306,1
R-HSA-453279,Mitotic G1 phase and G1/S transition,1/108,149/11091,0.769586753735698,0.812172582005657,0.749254422193273,4173,1
R-HSA-446652,Interleukin-1 family signaling,1/108,153/11091,0.778551087710706,0.820012388239679,0.756486886844411,9173,1
R-HSA-199977,ER to Golgi Anterograde Transport,1/108,154/11091,0.780737637585203,0.820696650532477,0.757118140053616,2157,1
R-HSA-9013148,CDC42 GTPase cycle,1/108,155/11091,0.782902795776736,0.82135578181685,0.757726209127313,5295,1
R-HSA-5633007,Regulation of TP53 Activity,1/108,160/11091,0.793414899256852,0.830752070986587,0.766394577610334,9156,1
R-HSA-168898,Toll-like Receptor Cascades,1/108,169/11091,0.811081454371311,0.847588056035773,0.781926296520288,6441,1
R-HSA-5619115,Disorders of transmembrane transporters,1/108,176/11091,0.823779835620509,0.859176625432328,0.792617111575654,6507,1
R-HSA-5663202,Diseases of signal transduction by growth factor receptors and second messengers,3/108,459/11091,0.830259094258002,0.864246308642832,0.797294051734369,22866/5295/5526,3
R-HSA-6791226,Major pathway of rRNA processing in the nucleolus and cytosol,1/108,185/11091,0.83887089949696,0.869819534624033,0.802435525732401,23246,1
R-HSA-948021,Transport to the Golgi and subsequent modification,1/108,185/11091,0.83887089949696,0.869819534624033,0.802435525732401,2157,1
R-HSA-6798695,Neutrophil degranulation,3/108,480/11091,0.852360419491206,0.882093922496713,0.813759029624407,290/5284/6616,3
R-HSA-8868773,rRNA processing in the nucleus and cytosol,1/108,195/11091,0.854140625435964,0.882226487394207,0.81388132485805,23246,1
R-HSA-196854,Metabolism of vitamins and cofactors,1/108,198/11091,0.858435395690293,0.884950774707754,0.816394564484977,8029,1
R-HSA-5617833,Cilium Assembly,1/108,201/11091,0.862604844835725,0.886231111604091,0.817575715022106,192668,1
R-HSA-6811442,Intra-Golgi and retrograde Golgi-to-ER traffic,1/108,202/11091,0.863967441415866,0.886231111604091,0.817575715022106,27333,1
R-HSA-9705683,SARS-CoV-2-host interactions,1/108,203/11091,0.865316648535628,0.886231111604091,0.817575715022106,6441,1
R-HSA-68877,Mitotic Prometaphase,1/108,205/11091,0.867975414548576,0.886231111604091,0.817575715022106,5526,1
R-HSA-72312,rRNA processing,1/108,205/11091,0.867975414548576,0.886231111604091,0.817575715022106,23246,1
R-HSA-1428517,Aerobic respiration and respiratory electron transport,1/108,215/11091,0.880508969790586,0.89560340927271,0.82622195060049,10873,1
R-HSA-6805567,Keratinization,1/108,215/11091,0.880508969790586,0.89560340927271,0.82622195060049,7062,1
R-HSA-8951664,Neddylation,1/108,246/11091,0.912342312636494,0.926218241345794,0.854465083677965,55827,1
R-HSA-913531,Interferon Signaling,1/108,269/11091,0.930382875274901,0.942740902081209,0.869707751180773,3306,1
R-HSA-1852241,Organelle biogenesis and maintenance,1/108,296/11091,0.946915846603785,0.957458332317976,0.883285037502095,192668,1
R-HSA-9694516,SARS-CoV-2 Infection,1/108,299/11091,0.948493366659568,0.957458332317976,0.883285037502095,6441,1
R-HSA-446203,Asparagine N-linked glycosylation,1/108,304/11091,0.951019996917051,0.958197506327745,0.883966948475034,2157,1
R-HSA-983168,Antigen processing: Ubiquitination & Proteasome degradation,1/108,309/11091,0.953423776277936,0.958810351285156,0.88453231697507,25847,1
R-HSA-3700989,Transcriptional Regulation by TP53,1/108,362/11091,0.972717887710978,0.976374721875305,0.900735994160542,9156,1
R-HSA-983169,Class I MHC mediated antigen processing & presentation,1/108,381/11091,0.977492636075103,0.979326580983312,0.903459175833215,25847,1
R-HSA-9679506,SARS-CoV Infections,1/108,414/11091,0.983899070698036,0.983899070698036,0.907677439555846,6441,1
